Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure

Here are the Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Dapagliflozin reduces systemic inflammation in patients with deeply pigmented, dapagliflozin reduces systemic scleroderma, dapagliflozin reduces systemic racism, dapagliflozin reduces synonyms, dapagliflozin reduces systemic inflammation in patients with cirrhosis, dapagliflozin reduces systemic inflammation in gulf, dapagliflozin reduces systemic inflammation examples, dapagliflozin reduces systemic disease, dapagliflozin reduces systemic inflammation in the body, dapagliflozin reduces pdf.

Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure

Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on systemic and cardiac inflammation and cardiac fibrosis. Research and design

methods: This randomized placebo-controlled clinical trial enrolled 62 adult patients (mean age 62, 17% female) with type 2 diabetes (T2D) without known heart failure. Subjects were randomized to 12 months of daily 10 mg dapagliflozin or placebo. For all patients, blood/plasma samples and cardiac magnetic resonance imaging (CMRI) were obtained at time of randomization and at the end of 12 months. Systemic inflammation was assessed by plasma IL-1B, TNFα, IL-6 and ketone levels and PBMC mitochondrial respiration, an emerging marker of sterile inflammation. Global myocardial strain was assessed by feature tracking; cardiac fibrosis was assessed by T1 mapping to calculate extracellular volume fraction (ECV); and cardiac tissue inflammation was assessed by T2 mapping.

Results: Between the baseline and 12-month time point, plasma IL-1B was reduced (− 1.8 pg/mL, P = 0.003) while ketones were increased (0.26 mM, P = 0.0001) in patients randomized to dapagliflozin. PBMC maximal oxygen consumption rate (OCR) decreased over the 12-month period in the placebo group but did not change in patients receiving dapagliflozin (− 158.9 pmole/min/106 cells, P = 0.0497 vs. − 5.2 pmole/min/106 cells, P = 0.41), a finding consistent with an anti-inflammatory effect of SGLT2i. Global myocardial strain, ECV and T2 relaxation time did not change in both study groups. Clinical Trial.gov Registration: NCT03782259. © The Author(s) 2024.

Authors : Wang D.D.; Naumova A.V.; Isquith D.; Sapp J.; Huynh K.A.; Tucker I.; Balu N.; Voronyuk A.; Chu B.; Ordovas K.; Maynard C.; Tian R.; Zhao X.-Q.; Kim F.

Source : BioMed Central Ltd